Robert L. Brainin - 16 Jul 2025 Form 4 Insider Report for CHAMPIONS ONCOLOGY, INC. (CSBR)

Reporting relationship: CEO, Director
Issuer ticker: CSBR
Reported as of: 16 Jul 2025
Net transaction value: +$5,460,000
SEC form: 4
Accepted by SEC: 30 Jan 2026, 15:55:35 UTC
Prior SEC filing: 30 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Robert L. Brainin

Filing notes and source

Key filing fact

Robert L. Brainin filed Form 4 for CHAMPIONS ONCOLOGY, INC. (CSBR) on 30 Jan 2026.

Key facts

This page summarizes Robert L. Brainin's Form 4 filing for CHAMPIONS ONCOLOGY, INC. (CSBR).
6 reported transactions and 6 derivative rows are listed below.
Accepted by SEC: 30 Jan 2026, 15:55.

Change

Previous filing in this sequence was filed on 30 Jan 2026.
Current net transaction value: +$5,460,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002088015 Primary reporting owner

Brainin Robert Lawrence

Relationship: CEO, Director
Address: C/O CHAMPIONS ONCOLOGY, INC, ONE UNIVERSITY PLAZA, SUITE 307, HACKENSACK
Signature: /s/ Robert L. Brainin
Signature date: 30 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CSBR transaction Derivative

Option to purchase Common Stock

Award

Transaction value: $1,755,000
Shares: +225,000
Change %: +303%
Price: $7.80
Shares after: 299,163
Date: 16 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 225,000
Exercise price: $7.80
Footnotes: F1

CSBR transaction Derivative

Option to purchase Common Stock

Award

Transaction value: $487,500
Shares: +62,500
Change %: +21%
Price: $7.80
Shares after: 361,663
Date: 16 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 62,500
Exercise price: $7.80
Footnotes: F2

CSBR transaction Derivative

Option to purchase Common Stock

Award

Transaction value: $487,500
Shares: +62,500
Change %: +17%
Price: $7.80
Shares after: 424,163
Date: 16 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 62,500
Exercise price: $7.80
Footnotes: F3

CSBR transaction Derivative

Option to purchase Common Stock

Award

Transaction value: $1,170,000
Shares: +150,000
Change %: +35%
Price: $7.80
Shares after: 574,163
Date: 16 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 150,000
Exercise price: $7.80
Footnotes: F4

CSBR transaction Derivative

Option to purchase Common Stock

Award

Transaction value: $780,000
Shares: +100,000
Change %: +17%
Price: $7.80
Shares after: 674,163
Date: 16 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $7.80
Footnotes: F5

CSBR transaction Derivative

Option to purchase Common Stock

Award

Transaction value: $780,000
Shares: +100,000
Change %: +15%
Price: $7.80
Shares after: 774,163
Date: 16 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $7.80
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

The options vest and become exercisable as follows: 25% will vest on the one-year anniversary of the grant date on July 16, 2026; the balance will vest ratably at a rate of 1/36th each month thereafter.

Footnote F2

The options will vest and be exercisable if the Company achieves EBITDA of $25 million over any consecutive four quarter period (based on the Company's fiscal year).

Footnote F3

The options will vest and be exercisable when $15 million of the Company's data revenue is recognized over any consecutive four quarter period (based on the Company's fiscal year).

Footnote F4

The options will vest and be exercisable if (i) the Company achieves EBITDA of $35 million over any consecutive four quarter period (based on the Company's fiscal year) or (ii) when $30 million of the Company's data revenue is recognized over any consecutive four quarter period (based on the Company's fiscal year).

Footnote F5

The options will vest and be exercisable on the first date on which the average closing price (rounded to the nearest penny) of the Company's listed stock for the then previous forty five (45) calendar days is equal to or greater than the $16.00 Strike Price.

Footnote F6